Abu Dhabi, United Arab Emirates – March 6, 2025:
Burjeel Holdings, one of the region’s leading healthcare providers, has announced strong financial results for the year 2024, reporting a 10.5% increase in revenue. This growth was fueled by a rise in patient visits and an expansion of high-quality, specialized medical services across the UAE and Saudi Arabia.
The Group recorded AED 5 billion in total revenue for 2024, welcoming over 6.5 million patients—a 7.5% increase from the previous year. This rise in footfall reflects the trust patients continue to place in Burjeel’s expert care and advanced medical facilities.
Among the standout achievements was the exceptional performance of Burjeel Medical City, which saw an 18.4% revenue increase and a 26.3% jump in patient numbers. Oncology services were a major contributor, with more than 15,000 cancer procedures and over 8,500 radiation sessions delivered in 2024 alone.
Burjeel’s hospitals played a key role in the year’s success, especially in complex and life-saving specialties such as organ transplants, orthopedics, neurosurgery, and women’s health. The Group made headlines with several medical firsts in the UAE, including the country’s first pediatric liver transplant and an ABO-incompatible kidney transplant—both completed with zero complications.
In parallel, Burjeel strengthened its footprint in Saudi Arabia, opening 29 physiotherapy centers in 10 cities and preparing to launch a Day Surgery Center in Riyadh. Through a joint venture with global health group Keralty, Burjeel is also introducing a new healthcare model in the Kingdom that focuses on prevention, early detection, and improving overall community wellness.
Back in the UAE, the Group opened two advanced Day Surgery Centers and four community-focused medical centers, improving access to care and expanding its referral network. These efforts underline Burjeel’s commitment to bringing expert care closer to where people live and work.
The Group also made significant progress in fertility care, launching the UAE’s largest fertility center, and took a major step in medical research by establishing the Burjeel Cancer Institute and the Onco-Helix Co-Lab, a cutting-edge molecular diagnostics lab.
Despite ongoing investments in growth, such as staffing and facility development, Burjeel maintained strong financial health. The Group ended 2024 with an EBITDA of AED 959 million (excluding one-time costs), and a net profit before taxes and one-offs of AED 450 million.
Also Read: Burjeel Holdings acquires 100% stake in Makkah’s specialist physiotherapy center
Looking ahead, Burjeel remains confident in its ability to grow further in 2025. With plans to optimize operations, scale up high-performing services, and continue regional expansion, the Group aims to deliver even more value to patients, families, and communities across the region.
